Alzheimer's Disease Clinical Trials in Ohio

22 recruiting studies across 2 cities

Browse by City

All Trials in Ohio

Phase

Trial	Phase	Sponsor	Dist.
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)	Phase 2	Alzheimer's Disease Cooperative Study (ADCS)	<1 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)	Phase 3	Karuna Therapeutics	<1 mi
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)	Phase 3	Karuna Therapeutics	<1 mi
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)	—	University of Southern California	<1 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies	Phase 3	Hoffmann-La Roche	<1 mi
Delirium Identification in Older Patients With Alzheimer's and Other Related Dementias In the Emergency Department	—	Ohio State University	<1 mi
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease	N/A	InSightec	<1 mi
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment	Phase 1	Mark Tuszynski	<1 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease	Phase 3	Bristol-Myers Squibb	<1 mi
Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's	N/A	Florida State University	<1 mi
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease	—	Douglas Scharre	<1 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease	Phase 2	Celgene	<1 mi
Learning Skills Together Family Caregiver Complex Intervention	N/A	Case Western Reserve University	<1 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant	Phase 3	Eidos Therapeutics, a BridgeBio company	<1 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)	Phase 2	Merck Sharp & Dohme LLC	10 mi
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD	Phase 3	Annovis Bio Inc.	10 mi
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis	Phase 2	MapLight Therapeutics	10 mi
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type	Phase 3	Suven Life Sciences Limited	10 mi
ACP-204 in Adults With Alzheimer's Disease Psychosis	Phase 2/3	ACADIA Pharmaceuticals Inc.	10 mi
[18F]PI-2620 Phase 3 Histopathological Study	Phase 3	Life Molecular Imaging Ltd	10 mi
Trial-Ready Cohort-Down Syndrome (TRC-DS)	—	University of Southern California	10 mi
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia	—	GAP Innovations, PBC	46 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.